Biotech | June 10, 2022
Bayer’s Vividion emerging as significant player in San Diego Biotech hub
Bayer now present in four of the largest biotechnology hubs in the United States
Bayer now present in four of the largest biotechnology hubs in the United States
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Based on a post hoc analysis, fewer required respiratory interventions
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Subscribe To Our Newsletter & Stay Updated
